Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Cash (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Cash for 6 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 305.77% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$24.0 million, a 96.39% decrease, with the full-year FY2024 number at -$18.6 million, down 152.54% from a year prior.
  • Change in Cash was -$2.3 million for Q3 2025 at Maxcyte, up from -$8.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $192.0 million in Q1 2022 to a low of -$130.6 million in Q2 2022.
  • A 5-year average of -$304357.9 and a median of -$4.5 million in 2025 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 225.15% in 2021; the steepest drop was 409.24% in 2021.
  • Maxcyte's Change in Cash stood at -$11.2 million in 2021, then plummeted by 185.55% to -$32.0 million in 2022, then surged by 91.66% to -$2.7 million in 2023, then tumbled by 240.49% to -$9.1 million in 2024, then surged by 75.18% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Change in Cash are -$2.3 million (Q3 2025), -$8.2 million (Q2 2025), and -$4.5 million (Q1 2025).